Bird & Bird has advised Oasmia Pharmaceutical AB (publ) in relation to its listing on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse). The Frankfurt Stock Exchange is Germany’s largest trading centre for securities. The application has been approved and the first day of trading was on 24 January. Oasmia is also listed on NASDAQ OMX Stockholm.
The Bird & Bird team was lead by Hans Svensson and included Staffan Seger and Caroline Carlshamre from the Stockholm office.
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.